Failure of omalizumab for treatment of severe adult atopic dermatitis

被引：136

作者：

Krathen, RA ^{[1
]}

Hsu, S ^{[1
]}

机构：

[1] Baylor Coll Med, Dept Dermatol, Houston, TX 77030 USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2005年 / 53卷 / 02期

关键词：

D O I：

10.1016/j.jaad.2005.02.014

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Atopic dermatitis has been associated with elevated levels of IgE. Omalizumab is a monoclonal anti-IgE antibody currently approved for the treatment of asthma. We report the failure of omalizumab to improve atopic dermatitis in 3 patients when administered for 4 months.

引用

页码：338 / 340

页数：3

共 20 条

[1] Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma [J].

Ayres, JG ;

Higgins, B ;

Chilvers, ER ;

Ayre, G ;

Blogg, M ;

Fox, H .

ALLERGY, 2004, 59 (07) :701-708

[2] Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma [J].

Berger, W ;

Gupta, N ;

McAlary, M ;

Fowler-Taylor, A .

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2003, 91 (02) :182-188

[3] The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma [J].

Buhl, R ;

Hanf, G ;

Solèr, M ;

Bensch, G ;

Wolfe, J ;

Everhard, F ;

Champain, K ;

Fox, H ;

Thirlwell, J .

EUROPEAN RESPIRATORY JOURNAL, 2002, 20 (05) :1088-1094

[4] Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma [J].

Busse, W ;

Corren, J ;

Lanier, BQ ;

McAlary, M ;

Fowler-Taylor, A ;

Della Cioppa, G ;

van As, A ;

Gupta, N .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2001, 108 (02) :184-190

[5] Omalizumab improves asthma-related quality of life in patients with severe allergic asthma [J].

Finn, A ;

Gross, G ;

van Bavel, J ;

Lee, T ;

Windom, H ;

Everhard, F ;

Fowler-Taylor, A ;

Liu, J ;

Gupta, N .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2003, 111 (02) :278-284

[6] Omalizumab inhibits allergen challenge-induced nasal response [J].

Hanf, G ;

Noga, O ;

O'Connor, A ;

Kunkel, G .

EUROPEAN RESPIRATORY JOURNAL, 2004, 23 (03) :414-418

[7]

Holgate S, 2001, CURR MED RES OPIN, V17, P233

[8] Omalizumab and the immune system: an overview of preclinical and clinical data [J].

Johansson, SGO ;

Haahtela, T ;

O'Byrne, PM .

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2002, 89 (02) :132-138

[9] The treatment of atopic dermatitis with adjunctive high-dose intravenous immunoglobulin: a report of three patients and review of the literature [J].

Jolles, S ;

Hughes, J ;

Rustin, M .

BRITISH JOURNAL OF DERMATOLOGY, 2000, 142 (03) :551-554

[10]

Kuanprasert Natita, 2002, Australas J Dermatol, V43, P125, DOI 10.1046/j.1440-0960.2002.00573.x

← 1 2 →